BioPharma Resources

Drug Trial Radar · NCT05147805

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Aug 24, 2022

Primary completion

Mar 27, 2025

Study completion Mar 27, 2025

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Dec 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • Treprostinil PalmitilDrug

    Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.

  • PlaceboDrug

    Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Pulmonary Vascular Resistance at Week 16Time frame: Baseline to Week 16

Locations

92 sites in 17 countries. Site status is shown where the registry gives one.

  • USA025

    Phoenix, Arizona

  • USA022

    Scottsdale, Arizona

  • USA021

    Tucson, Arizona

  • USA023

    Sacramento, California

  • USA002

    West Hollywood, California

  • USA008

    Gainesville, Florida

  • USA005

    Jacksonville, Florida

  • USA007

    Orlando, Florida

  • USA011

    Tampa, Florida

  • USA010

    Winter Park, Florida

  • USA009

    Atlanta, Georgia

  • USA006

    Chicago, Illinois

  • USA001

    Chicago, Illinois

  • USA013

    Indianapolis, Indiana

  • USA014

    Iowa City, Iowa

  • USA003

    Kansas City, Kansas

  • USA102

    New York, New York

  • USA017

    New York, New York

  • USA016

    Dallas, Texas

  • USA012

    Denison, Texas

  • USA018

    Houston, Texas

  • ARG004

    Córdoba, Argentina

  • ARG001

    Córdoba, Argentina

  • ARG008

    Cuiudad Autónoma de Buenos Aires, Argentina

  • ARG009

    Quilmes, Buenos Aires, Argentina

  • ARG002

    Rosario, Santa Fe Province, Argentina

  • ARG006

    Rosario, Santa Fe Province, Argentina

  • ARG007

    San Miguel de Tucumán, Tucumán Province, Argentina

  • AUS005

    New Lambton Heights, New South Wales, Australia

  • AUS004

    Milton, Queensland, Australia

  • AUS001

    Woolloongabba, Queensland, Australia

  • AUS003

    Adelaide, South Australia, Australia

  • AUS002

    Hobart, Tasmania, Australia

  • AUT001

    Vienna, Austria

  • AUT002

    Linz, Upper Austria, Austria

  • BEL001

    Liège, Belgium

  • BEL003

    Anderlecht, Brussels Capital, Belgium

  • BEL002

    Leuven, Vlaams Brabant, Belgium

  • BRA001

    São Paulo, Brazil

  • BRA003

    Belo Horizonte, Minas Gerais, Brazil

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.